Capricor Therapeutics, Inc. (CAPR, Financial) experienced a notable stock price increase of 5.06%, reaching $18.69 per share with a trading volume of 692,811 shares and a turnover rate of 1.52%. The stock's price fluctuation was recorded at 6.61%.
Recent financial reports show Capricor Therapeutics generated a revenue of $2.26 million, with a net loss of $12.56 million, resulting in an earnings per share of -$0.38. The gross profit amounted to $1.90 million, and the price-to-earnings ratio stood at -18.32. Among the seven institutions providing ratings, all issued a "buy" recommendation for CAPR, with none suggesting a "hold" or "sell."
Within the biotechnology sector, which saw an overall increase of 0.57%, Capricor's peers like Replimune Group, Inc., and Exicure, Inc. experienced significant gains. Other active stocks in the sector included Virpax Pharmaceuticals, Inc., Exicure, Inc., and Molecular Templates, Inc., with turnover rates of 1891.80%, 156.42%, and 98.35%, respectively. Stocks with notable price fluctuations included Apollomics Inc C/Wts 01/04/2028, Ocean Biomedical Inc C/Wts 14/02/2028, and Virpax Pharmaceuticals, Inc., with amplitudes of 82.83%, 77.41%, and 72.75%.
Capricor Therapeutics is a biotechnology company focused on developing transformative cell and exosome therapies to redefine the treatment landscape for rare diseases. Its product portfolio includes CAP-1002, known as deramiocel, an allogeneic cardiac-derived cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. The company utilizes its proprietary StealthXTM platform for preclinical studies targeting vaccine delivery, oligonucleotides, proteins, and small molecules for treating and preventing various diseases.
